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Abstract. The intestinal and bronchoalveolar mucosae contribute to 
homeostasis by preventing the entrance of biological and chemical 
agents that could alter the stability of the system. In this review, we 
summarise the main effects of dietary supplementation with                 
spray-dried plasma (SDP), a complex mixture of biologically active 
functional components, on two models of acute inflammation; a 
murine model of intestinal inflammation, based on the 
administration of S. aureus enterotoxin B (SEB), and a model of 
acute lung inflammation, using mice challenged with 
lipopolysaccharide from E. coli (LPS). Oral SDP modulates the 
immune response of the intestinal mucosa and restores the barrier 
function of the epithelium, preventing most of the effects of SEB on 
defensin expression, tight-junction permeability and mucosal 
cytokine production. In the lung, SDP supplementation partially 
prevents the LPS-induced release of pro-inflammatory cytokines, an 
effect that involves the participation of the common mucosal 
immune system. In both models, the effects of SDP are mediated by 
an increased T-reg response and enhanced release of anti-
inflammatory cytokines that contribute to mucosal homeostasis. 
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Introduction 
 
 Spray-dried plasma (SDP) is a protein-rich product obtained from the 
industrial fractionation of blood from porcine and bovine animals 
slaughtered for human consumption. Blood is collected with an 
anticoagulant, centrifuged to separate blood cells and spray-dried using high 
pressure and a temperature over 80ºC for a very short period of time. With 
this procedure, proteins are not denaturalised and their biological activity is 
mostly preserved [1]. 
 At the end of the last century, SDP was initially proposed as a protein 
source for piglets [2]. Since then, many studies have demonstrated that SDP 
improves piglet and calf performance, and today it is widely used as an 
alternative to the use of antibiotics as growth promoters [3]. Numerous 
studies have shown that feeding SDP of either bovine or porcine origin 
reduces mortality and morbidity in various animal species challenged with 
pathogenic bacteria (E. coli, Salmonella), viruses (rotavirus, coronavirus, 
white spot syndrome virus) or protozoa (C. parvum) [4;5;6]. 
 In addition, a greater efficacy of SDP has been described in younger 
pigs which have a less mature immune system [7], or in pigs kept under less 
hygienic conditions [8]. 
 
1. Effects of SDP on acute intestinal inflammation 
 
 The gastrointestinal tract provides a protective interface between the 
internal milieu and the permanent challenge resulting from microorganisms 
and antigens derived from food present in the lumen. The intestinal mucosa 
regulates the penetration of luminal antigens and the generation of 
immunologic responses in the gut, and dysregulation of these barrier 
mechanisms causes intestinal inflammation [9]. 
 Since the host’s immune responses can be modulated by diet [10], the 
dietary approach offers a therapeutic potential in conditions associated with 
gut barrier dysfunction and inflammatory response. 
 
1.1. Intestinal barrier 
 
 A key function of the intestinal epithelium is to serve as a selective 
barrier allowing the uptake of nutrients while excluding toxins and 
microorganisms. Mucosal permeability mainly depends on the capacity of 
tight-junctions to efficiently seal the apical poles of epithelial cells. The 
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space between cells is occupied by interlocking proteins such as claudins, 
occludin or E-cadherin that bind scaffolding proteins such as ZO-1 and            
β-catenin which, in turn, link them to the cellular cytoskeleton [11]. An acute 
change of the intestinal barrier function contributes to disease pathogenesis, 
especially when the intestine is challenged by luminal antigens. Several 
bacterial products, such as Clostridium and Vibrio toxins, change the 
localisation of several tight-junction proteins [12] or reduce the number of 
strands in the tight-junction [13]. 
 Staphylococcal enterotoxin B (SEB) reduced the expression of β-catenin 
in a rodent model of intestinal inflammation [14] and SDP supplementation 
prevented this effect (Figure 1A). Moreover, SEB treatment significantly 
increased the flux of 4 kD FITC-dextran (FD4, a fluorescent tracer of 
paracellular permeability) across the intestinal wall and SDP 
supplementation prevented this effect (Figure 1B). The effects of SEB on 
intestinal permeability were similar to those described in SEB-injected mice 
(15). β-catenin expression was negatively correlated with FD4 flux, 
suggesting that the increases in dextran flux are paralleled by a reduction in 
β-catenin expression (Figure 1C). These results indicate that the increase in 
FD4 flux induced by SEB treatment is associated with a reduction in the 
tightness of the epithelial junction complex and that SDP dietary 
supplementation resulted in complete recovery. The effects of SDP 
supplementation in reducing a toxin-induced increase in mucosal 
permeability may prevent the passage of microbial and food antigens to the 
interstitial space, thereby avoiding local inflammation [16]. 
 Enterotoxins can also have indirect effects by inducing the release of 
pro-inflammatory cytokines such as IFN-γ and TNF-α. Both cytokines 
increase epithelial permeability by reducing the expression of β-catenin [17]. 
SEB also stimulates the secretion of IFN-γ and TNF-α from lymphocytes 
[18;19], which can disassemble tight-junction protein complexes [20] or 
reduce their expression [21;22], thus enhancing paracellular permeability of 
microvascular endothelial cells.  
 Mucosal homeostasis is also protected by mucosal defensins secreted by 
both Paneth cells and enterocytes. These are antimicrobial peptides that 
regulate the composition and number of luminal colonising microbes present 
in the small intestine, and they play an important role in reducing pathogen 
concentration in the intestinal lumen. Studies in humans indicate that 
reduced Paneth cell defensin expression may be a key pathogenic factor in 
ileal Crohn's disease, because it changes the profile of the colonising 
microbiota [23]. 
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Figure 1. SDP effects on intestinal barrier function in acute inflammation (with 
permission from Pérez-Bosque et al., 2006). Panel A shows representative images of 
β-catenin immunohistochemical localisation in jejunum from Control, SEB and  
SEB-SDP rats. Panel B shows the FITC-dextran (FD) flux across the intestinal wall 
of rat jejunum measured in an Ussing chamber. Results are expressed as means ± 
SEM (7-10 animals). Symbols indicate significant differences P<0.05; *SEB group 
vs Control group, #SEB-SDP group vs SEB group. Panel C shows the correlation 
between β-catenin expression and FD flux (P<0.001). 
 
 In rats, SEB reduces the expression of cryptdin 4 and β-defensin-1 
(Figure 2). Since cryptdin 4 has the ability to block IL-1β release from           
LPS-activated monocytes [24], decreased expression of this defensin would 
result in increased intestinal IL-1β production, rendering the intestine more 
susceptible to SEB-induced damage and contributing to pathogenesis of 
inflammatory bowel diseases. β-defensin-1 is constitutively expressed by 
enterocytes, and when its expression is reduced, there is increased 
proliferation of several major components of the intestinal microbiota, 
including Candida albicans, Bacteroides fragilis, Enterococcus faecalis and 
Escherichia coli [25]. SDP restored the physiological production of mucosal  
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Figure 2. Effects of SDP supplementation on cryptdin 4 (A) and β-defensin 1 (B) 
expression in acute inflammation. Expression determined by real time PCR. Data 
are the mean ± SEM of 7-8 rats. Symbols indicate significant differences P<0.05; 
*SEB group vs Control group, #SEB-SDP group vs SEB group. 
 
defensins, indicating that plasma protein supplementation may contribute 
to maintenance of intestinal immune homeostasis by maintaining the 
production of natural innate antibacterial agents, as well as by regulating 
the production of pro-inflammatory cytokines. The possible relationship 
between the current effects of SDP on defensin expression, and previous 
observations showing that dietary plasma proteins induce changes in the 
microbiota profile associated with a higher resistance to dysbiosis [26], 
should be further explored. 
 
1.2. Intestinal immune response 
 
 Gut-associated lymphoid tissue (GALT) accounts for up to 80% of the 
mucosal immune system and is distributed along the intestine. It contains a 
broad network of secondary lymphoid organs, as well as a large number of 
lymphocytes, including several intestine-specific subpopulations [27]. Upon 
activation, the intestinal immune system coordinates a strong inflammatory 
response against invasive pathogenic bacteria (thus promoting protection) 
while providing inhibitory mechanisms to prevent an excessive response 
against commensal bacteria (thus promoting tolerance). However, if the 
immune system is stimulated and the response is not controlled, tissue may 
be damaged [18]. 
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 SEB administration induces a recruitment of neutrophils [28] and 
eosinophils [29]. The dietary inclusion of SDP does not modify the SEB-
induced effects on neutrophil infiltration, but does reduce eosinophil 
infiltration and the degree of cell degranulation. The SEB challenge also 
increases the activation of intestinal T-helper lymphocytes present in Peyer’s 
patches (PP), in mucosal lamina propria and in the intraepithelial 
compartment [28;30]. Furthermore, dietary supplementation with SDP 
prevents the SEB-induced activation of T-helper lymphocytes in all the 
above mentioned intestinal compartments (Figure 3A). SDP reduces the 
expression of mucosal pro-inflammatory cytokines [19], which is paralleled 
by a reduction in intestinal activated T cells (Figure 3B), consistent with the 
fact that activated T-helper lymphocytes release pro-inflammatory cytokines 
to amplify the immune response [31]. Bosi et al. [32] observed that pigs 
challenged with E. coli K88 and fed SDP had a lower intestinal expression 
of pro-inflammatory cytokines. The effect of SDP on the mucosal cytokine 
profile reduces mucosal inflammation and prevents changes in mucosal 
permeability and tight-junctional protein expression following SEB 
administration [14]. 
 The inducible regulatory T cell (T-reg) population is another component 
of the mucosal immune system that maintains immunological 
unresponsiveness to self-antigens and suppresses excessive immune 
responses that can be deleterious to the host [33]. T-reg cells mediate 
peripheral T cell tolerance to antigens derived from dietary origin or from 
the commensal flora. In addition, after antigenic stimulation, T-reg 
lymphocytes can specifically inhibit the immune response of activated T-
helper cells [34], through the expression of characteristic cytokines such as 
transforming growth factor-β and IL-10, distinct from either Th1 or Th2 
cells. 
  SDP supplementation increased IL-10 production in SEB-challenged 
rats at both intestinal (Peyer’s patches and intestinal mucosa) and systemic 
levels [19]. Dietary supplementation with plasma proteins increases the 
mucosal expression of IL-10, which suggests the involvement of this anti-
inflammatory cytokine in regulating the production of pro-inflammatory 
cytokines (Figure 3C). This SDP effect on IL-10 contributes to intestinal 
homeostasis, since this cytokine is involved in the control of the intestinal 
pathology caused by T cell and innate immune cell activation. In view of the 
role of IL-10 in the amelioration of intestinal inflammation [35], it is worth 
noting that SDP can also increase mucosal IL-10 in absence of any 
challenge. 
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 The observation that the effects of SEB on the release of systemic           
pro-inflammatory cytokines are small is in agreement with previous    results 
in the spleen [28] and indicates that SEB has little effect on the peripheral 
immune system. However, the increase in IL-10 concentration in serum is 
highly correlated to a reduction in the TNF-α concentration (Figure 3D). 
 
 
 
Figure 3. SDP effects on mucosal immune response in acute intestinal 
inflammation (with permission from Pérez-Bosque et al., 2008). Panel A shows 
activated T lymphocytes in the intestinal lamina propria. Activated T cells were 
immunolocalised with specific antibodies on jejunal slides from Control, SEB and 
SEB-SDP rats. Results are expressed as means ± SEM (5-6 animals). Symbols 
indicate significant differences P<0.05; *SEB group vs Control group, #SEB-SDP 
group vs SEB group. Panel B shows the correlation between the number of activated 
T cells in the intestinal lamina propria and TNF-α mucosal concentration. The 
correlation coefficient was R2=0.6971 (P<0.001). The correlation of TNF-α and IL-
10 concentration in the intestinal mucosa and in serum is shown in panels C and D, 
respectively. 
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2. Effects of SDP on acute lung inflammation 
 
 The observation that SDP not only modulates GALT homeostasis [29] 
but also affects lymphoid tissue populations in peripheral tissues such as the 
spleen [36;28] and lung [37] has led to the hypothesis that plasma 
supplements may also modulate the immune response in non-intestinal 
mucosal tissues. This hypothesis is supported by the existence of the 
common mucosal immune system that connects the lymphoid tissue of the 
gut to the other mucosal areas, that is, nasopharyngeal, bronchoalveolar and 
genitourinary mucosae [38]. 
 
2.1. Common mucosal immune system 
 
 The respiratory and gastrointestinal tracts share some structural 
similarities. Both have an extensive luminal surface area, which is protected 
from commensal bacteria, pathogens and foreign antigens by a selective 
epithelial barrier [39] and an overlying mucus-gel layer [40]. These 
epithelial surfaces cover a mucosa-associated lymphoid tissue composed of 
resident lymphocytes. This lymphoid tissue regulates antigen sampling, 
lymphocyte trafficking and mucosal host defence [38]. Together with the 
genitourinary tract, they represent the main sites of intersection between the 
environment and the host. 
 An additional feature of mucosal barrier tissues is their contact with 
beneficial microbiota. Therefore, these tissues must protect the host from 
pathogenic challenges while at the same time maintaining a peaceful 
coexistence with the resident microbiota [41]. 
 There is much evidence suggesting that the mucosal immune system is a 
system-wide organ. Studies have demonstrated that stimulation in one 
compartment of the mucosal immune system can lead to changes in distal 
areas. For example, intranasal immunisation results in vaginal protection 
against genital infection with herpes simplex virus type 2 [42]. Furthermore, 
the use of antibiotics in neonates has been associated with a greater risk of 
developing asthma [43], which suggests that alterations in the gut microflora 
can have an effect on the lungs. Collectively, such studies suggest that the 
mucosal immune system is actually a large interconnected network with 
individual components efficiently sharing information [44]. 
 
2.2. Pro-inflammatory immune response 
 
 In a mouse model of acute lung inflammation induced by inhalation of 
LPS, the pulmonary response is characterised by leukocyte migration 
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accompanied by a massive release of pro-inflammatory cytokines and 
chemokines (Figure 4A), which recruit monocytes and neutrophils into the 
lung airway and into the lung tissue [45]. Dietary inclusion of SDP reduces 
the innate immune response to LPS inhalation. The reduction in leukocyte 
numbers in bronchoalveolar lavage fluid (BALF) and lung tissue, the lower 
concentration of pro-inflammatory cytokines and chemokines in BALF and 
the lower iNOS expression in lung tissue all suggest a dietary-dependent 
reduction in the chemical mediators responsible for acute lung injury.  
 
 
 
Figure 4. SDP effects on mucosal pro-inflammatory immune response in acute 
lung inflammation (with permission from Maijò et al., 2012a,b). Panel A shows the 
correlation between leukocyte recruitment into lung airway and chemokine CCL2 
concentration in bronchoalveolar lavage fluid (BALF). Panel B and panel C show the 
percentage of activated neutrophils (B) and activated Th lymphocytes (C) in the lung 
airway. Results are expressed as means ± SEM (5-6 animals). Symbols indicate 
significant differences P<0.05; *LPS group vs Control group, #LPS-SDP group vs 
SEB group. Panel D shows the correlation between the number of activated Th 
lymphocytes in BALF and IL-2 BALF concentration. 
Anna Pérez-Bosque & Miquel Moretó 126 
 The LPS challenge increased the percentage of neutrophils by 70% 
[45]. The primary function of neutrophils is to contain and kill invading 
microbial pathogens [46]. In BALF and lung tissue, LPS increased the 
proportion of activated neutrophils (Figure 4B) and of activated 
monocytes [45], as a consequence of the release of large amounts of 
chemokines. SDP supplementation reduces the percentage of activated 
neutrophils and monocytes in the lung airway. The effects of SDP on the 
response of the innate immune system present in the lung are relevant 
because this system plays an important role in mediating defence against 
pathogens, detecting tissue damage and regulating tissue health and 
integrity [47]. Therefore, the lower cell migration and diminished 
activation of inflammatory cells in pulmonary tissue may reduce potential 
damage in respiratory epithelium and vascular endothelium associated with 
the inflammatory response. 
 LPS challenge also promotes the activation of Th lymphocytes at both 
local (lung tissue; Figure 4C) and systemic (blood) levels. These effects 
are accompanied by enhanced release of IL-2 in the lung (Figure 4D); this 
cytokine (almost exclusively produced by activated Th cells) promotes 
proliferation of lymphocytes, macrophages and NK cells [48]. SDP 
supplementation also reduces the percentage of activated Th lymphocytes 
and prevents the release of IL-2. This effect is consistent with the                   
anti-inflammatory response previously described for plasma supplements 
[19]. 
 
2.3. Regulatory response during acute lung inflammation 
 
 The LPS challenge does not modify the percentage of T-reg cells 
(Figure 5A); however, dietary SDP inclusion increases the percentage of 
these cells and also reduces the T-activated:T-reg cell ratio (Figure 5B).              
T-reg cells reduce inflammation by counteracting the effects of other Th 
cells and contribute to suppression of innate and adaptive immune responses 
[49;50]. 
 SDP promotes IL-10 production in the lung of inflamed mice, and the 
increases in the concentration of this cytokine are paralleled by increases in 
the percentage of T-reg cells (Figure 5C). Other studies carried out using a 
LPS model of acute lung inflammation in rats have demonstrated that 
treatment with IL-10 after endotoxin instillation protects against acute lung 
injury, possibly by suppressing pulmonary infiltration of activated 
neutrophils [51]. In the LPS-induced lung inflammation model, as in the 
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SEB model of intestinal inflammation, it has been shown that the dietary 
modulation of intestinal inflammation is mediated by an increase in mucosal 
IL-10 expression, which reduces the release of pro-inflammatory cytokines 
[19;52] (Figure 5D). 
 
 
 
Figure 5. SDP effects on mucosal anti-inflammatory immune response in acute 
lung inflammation (with permission from Maijò et al., 2012b). Panel A and panel B 
show the percentage of the regulatory T lymphocytes (T-reg) (A) and the ratio 
between activated Th lymphocytes and T-reg cells (B) in the lung airway. Results are 
expressed as means ± SEM (5-6 animals). Symbols indicate significant differences 
P<0.05; *LPS group vs Control group, #LPS-SDP group vs SEB group. Panel C 
shows the correlation between T-reg into lung airway and the concentration of the 
anti-inflammatory cytokine IL-10 in bronchoalveolar lavage fluid (BALF). Panel D 
shows TNF-α and IL-10 concentrations in BALF. 
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3. Mode of action of SDP 
 
 SDP is a highly complex mixture of functional peptides and proteins 
such as immunoglobulins and growth factors, with a high proportion                    
of albumin [53]. As summarised by Petschow et al. [54], plasma 
supplements contribute to homeostasis by neutralising endotoxin in the 
intestinal lumen, promoting a stable microbiota, maintaining the gut barrier 
function and preserving the immune balance both in intestinal and 
peripheral tissues. 
 The mechanism by which oral plasma supplements modulate 
peripheral inflammation is not completely understood. However, there is 
increasing evidence that signals initiated in the intestinal lumen of 
different origin (dietary functional components, changes in the microflora, 
the presence of microbial cell wall components and even bacterial secreted 
products) can interact with the intestinal mucosa and have the capacity to 
regulate immune responses outside the gastrointestinal tract [55]. Plasma 
supplements ameliorate the inflammatory response by increasing the 
number of T-regs in the inflamed colon as well as by enhancing                          
IL-10 release [56]. Therefore, there is evidence indicating that plasma 
supplements modulate the abundance of T-regs in the intestine (the 
inductor site) and stimulated blood and lung T-regs in the lung model                      
(the effector site), both interconnected by the common mucosal system 
[55]. 
 The mechanism of action of SDP is probably not unique. SDP contains 
a high proportion of immunoglobulins that can bind a variety of potential 
antigens in the lumen, preventing their attachment to the mucosa [32]. This 
is the mechanism claimed to explain the beneficial effects of SDP in the 
prevention of viral gastroenteritis in children [57], and in the reduction of 
diarrhoea in pigs [58] and in acquired immune deficiency syndrome 
patients infected with C. parvum [59]. However, it must be considered that 
over 250 peptides have been identified in plasma [53] and most of them 
will retain some biological function after spray-drying [1]. SDP may 
contain a fraction of natural antibodies that will contribute to immune 
homeostasis, enhancing anti-inflammatory IL-10 production, as suggested 
by Petschow et al. [60]. The presence of bioactive peptides in SDP may 
also cause changes in the intestinal microbiota profile. For example, SDP 
can inhibit the growth of pathogenic bacteria [61;58]. 
 Animal plasma supplementation can also change the microbiota profile. 
Ovine Ig may alter the intestinal environment through a specific enrichment 
of Lactobacillus strains and depletion of enterobacteria [62], although 
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studies in piglets have yielded conflicting results [6;63]. In rats, the analysis 
of caecal microbiota showed that animals fed porcine SDP presented 
increased richness of the intestinal ecosystem [26]. Finally, it is worth noting 
that animal plasma supplements contain growth factors, cytokines and 
biologically active compounds that may also directly interact with mucosal 
receptors present both in enterocytes and ib dendritic cells, or that can reach 
the subepithelial compartment across the Peyer’s patch M cells, as happens 
with food-derived peptides [64]. This is a largely unexplored area that 
deserves further attention. 
 
4. Conclusions 
 
 Supplements prepared from animal plasma of porcine, bovine or ovine 
origin have been shown to contribute to gut homeostasis and act at luminal and 
mucosal levels. The main targets are the regulation of the intestinal barrier and 
the gut-associated immune system, which connects and modulates other 
mucosal areas, promoting the proliferation of regulatory lymphocytes and the 
expression of anti-inflammatory cytokines which presumably mediate most of 
its beneficial physiological effects. The mechanism by which plasma 
supplements initiate the regulatory responses is probably not unique but 
involves luminal mechanisms, with changes in the microbiota profile, direct or 
indirect interaction with enterocytes or with immune intestinal cells, and steps 
connecting the gut-associated phenomena with peripheral mucosal areas also 
exposed to the external environment. A better insight into the mechanisms 
implicated and a deeper knowledge of the specific plasma components 
involved are necessary to gain acceptance of these products. 
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